ABIVAX SIGNS AGREEMENT WITH THE FINLAY INSTITUTE
ABIVAX SIGNS AGREEMENT WITH THE FINLAY INSTITUTE
November 12, 2014
- Details
- Published on Wednesday, 12 November 2014 13:58
ABIVAX signs agreement with the Finlay Institute to commercialise meningococcal and typhoid vaccines in Asia and Latin America. Under the terms of the agreement, ABIVAX will gain exclusive and non-exclusive distribution rights for three vaccines currently marketed successfully by The Finlay Institute in Cuba :
- Typhoid: vax‐TyVi – targeting Typhoid
- Meningococcal: VA‐MENGOC‐BC – targeting Groups B & C Meningococcus
- Leptospirosis: vax‐SPIRAL – targeting Leptospirosis